HK1131745A1 - Neurotoxic oligomers - Google Patents
Neurotoxic oligomersInfo
- Publication number
- HK1131745A1 HK1131745A1 HK09109775.3A HK09109775A HK1131745A1 HK 1131745 A1 HK1131745 A1 HK 1131745A1 HK 09109775 A HK09109775 A HK 09109775A HK 1131745 A1 HK1131745 A1 HK 1131745A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disease
- compositions
- methods
- alleviation
- alzheimer
- Prior art date
Links
- 231100000189 neurotoxic Toxicity 0.000 title 1
- 230000002887 neurotoxic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000004849 abnormal protein aggregation Effects 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 229910001431 copper ion Inorganic materials 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21477900P | 2000-06-28 | 2000-06-28 | |
| US24217700P | 2000-10-23 | 2000-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1131745A1 true HK1131745A1 (en) | 2010-02-05 |
Family
ID=26909346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK09109775.3A HK1131745A1 (en) | 2000-06-28 | 2009-10-22 | Neurotoxic oligomers |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7618634B2 (xx) |
| EP (1) | EP1296705B1 (xx) |
| JP (1) | JP2004501204A (xx) |
| CN (2) | CN1450908A (xx) |
| AU (2) | AU6882801A (xx) |
| CA (1) | CA2413354C (xx) |
| DK (1) | DK1296705T3 (xx) |
| ES (1) | ES2389811T3 (xx) |
| HK (1) | HK1131745A1 (xx) |
| NZ (1) | NZ523428A (xx) |
| WO (1) | WO2002000245A1 (xx) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2006014638A2 (en) * | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
| WO2006110621A2 (en) * | 2005-04-11 | 2006-10-19 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| CN103265495B (zh) | 2005-12-29 | 2016-11-16 | 莱西肯医药有限公司 | 多环氨基酸衍生物及其使用方法 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US20090246191A1 (en) * | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20110166035A1 (en) * | 2009-11-24 | 2011-07-07 | Probiodrug Ag | Novel diagnostic method |
| WO2011106732A1 (en) | 2010-02-25 | 2011-09-01 | Wyeth Llc | Pet monitoring of ab-directed immunotherapy |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| DE102019129221B4 (de) * | 2019-10-29 | 2022-05-12 | Chiracon Gmbh | Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
| CN117024554A (zh) * | 2023-05-30 | 2023-11-10 | 中国人民解放军空军军医大学 | 一种Aβ1-42寡聚体存储液的制备方法及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2001
- 2001-06-28 JP JP2002505026A patent/JP2004501204A/ja active Pending
- 2001-06-28 CN CN01813312A patent/CN1450908A/zh active Pending
- 2001-06-28 ES ES01947033T patent/ES2389811T3/es not_active Expired - Lifetime
- 2001-06-28 NZ NZ523428A patent/NZ523428A/en not_active IP Right Cessation
- 2001-06-28 DK DK01947033.5T patent/DK1296705T3/da active
- 2001-06-28 US US10/312,437 patent/US7618634B2/en not_active Expired - Fee Related
- 2001-06-28 WO PCT/AU2001/000786 patent/WO2002000245A1/en active Application Filing
- 2001-06-28 EP EP01947033A patent/EP1296705B1/en not_active Expired - Lifetime
- 2001-06-28 AU AU6882801A patent/AU6882801A/xx active Pending
- 2001-06-28 AU AU2001268828A patent/AU2001268828C1/en not_active Ceased
- 2001-06-28 CN CN2008101298934A patent/CN101411876B/zh not_active Expired - Fee Related
- 2001-06-28 CA CA2413354A patent/CA2413354C/en not_active Expired - Fee Related
-
2009
- 2009-05-14 US US12/466,094 patent/US8318171B2/en not_active Expired - Fee Related
- 2009-10-22 HK HK09109775.3A patent/HK1131745A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101411876A (zh) | 2009-04-22 |
| EP1296705A1 (en) | 2003-04-02 |
| CA2413354C (en) | 2014-04-01 |
| CN101411876B (zh) | 2013-01-16 |
| US20090297538A1 (en) | 2009-12-03 |
| AU2001268828B2 (en) | 2006-07-06 |
| JP2004501204A (ja) | 2004-01-15 |
| DK1296705T3 (da) | 2012-09-17 |
| US8318171B2 (en) | 2012-11-27 |
| EP1296705A4 (en) | 2005-04-20 |
| US20040013680A1 (en) | 2004-01-22 |
| US7618634B2 (en) | 2009-11-17 |
| AU6882801A (en) | 2002-01-08 |
| WO2002000245A1 (en) | 2002-01-03 |
| CN1450908A (zh) | 2003-10-22 |
| EP1296705B1 (en) | 2012-06-13 |
| NZ523428A (en) | 2008-03-28 |
| CA2413354A1 (en) | 2002-01-03 |
| AU2001268828C1 (en) | 2006-12-14 |
| ES2389811T3 (es) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1131745A1 (en) | Neurotoxic oligomers | |
| WO2003000714A3 (en) | Compositions and methods for preventing protein aggregation in neurodegenerative diseases | |
| IN2006KO01346A (xx) | ||
| HK1087398A1 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
| MXPA04006039A (es) | Metodo para el tratamiento de afecciones vasculares y neuronales perifericas. | |
| IL111078A0 (en) | Inhibitors of beta-amyloid protein production | |
| WO2006042249A3 (en) | Methods and compositions for treating migraine pain | |
| IL143313A0 (en) | Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases | |
| PT2527315E (pt) | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson | |
| MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
| GB0318447D0 (en) | Therapeutic agents | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| WO2002098444A3 (en) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis | |
| HK1096673A1 (en) | Compositions useful as inhibitors of protein kinases | |
| NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
| WO2005055944A3 (en) | Oligosaccharide compositions and use thereof in the treatment of infection | |
| BG105575A (en) | Method and agent for the treatment of cerebral ischaemia | |
| WO2005067908A3 (en) | Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease | |
| WO2007132292A3 (en) | Therapy for alzheimer's disease | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| WO2002094196A3 (en) | Method of treatment for cancers associated with elevated | |
| WO2006058720A3 (en) | Novel compounds for the treatment of neurological disorders | |
| WO2001058476A3 (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
| WO1999048489A3 (en) | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
| WO2001008637A3 (en) | Treatment of premenstrual syndrome and menopause |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180628 |